384338-20-9

Basic information

• Product Name: 1-benzyl-4-methylpiperidin-3-ol
• Synonyms: 1-benzyl-4-methylpiperidin-3-ol;4-Methyl-1-(phenylmethyl)-3-piperidinol;3-Piperidinol, 4-Methyl-1-(phenylMethyl)-;Trans-1-benzyl-4-methyl-piperidin-3-ol
• CAS NO: 384338-20-9
• Molecular Formula: C13H19NO
• Molecular Weight: 205.3
• Mol File: 384338-20-9.mol

Chemical Properties

• Boiling Point: 305.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.064
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.84±0.40(Predicted)
• CAS DataBase Reference: 1-benzyl-4-methylpiperidin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-methylpiperidin-3-ol(384338-20-9)
• EPA Substance Registry System: 1-benzyl-4-methylpiperidin-3-ol(384338-20-9)

Safety Data

• Hazardous Substances Data: 384338-20-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-benzyl-4-methylpiperidin-3-ol is used as an opioid receptor modulator for its potential therapeutic applications in managing pain and itching. Its interaction with opioid receptors suggests it could provide analgesic effects, making it a candidate for the development of pain relief medications.
1-benzyl-4-methylpiperidin-3-ol is also used as a potential treatment for substance use disorders, given its capacity to modulate opioid receptors, which may assist in managing withdrawal symptoms and cravings associated with opioid dependence.
Used in Chemical Synthesis:
In the field of organic chemistry, 1-benzyl-4-methylpiperidin-3-ol is utilized as a building block in the synthesis of other complex organic compounds, contributing to the development of new pharmaceuticals, agrochemicals, or other specialty chemicals.

Upstream product

• 32018-56-7 1-benzyl-4-methyl-1 ,2,3,6-tetrahydropyridine 
• 100-46-9 benzylamine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 100-39-0 benzyl bromide 
• 41979-39-9 4-piperidone hydrochloride 
• 32018-96-5 1-benzyl-4-methyl-piperidin-3-one 
• 6998-30-7 methylamine acetate 
• 23662-66-0 1-benzyl-4-methylpyridinium chloride 
• 100-44-7 benzyl chloride 
• 108-89-4 picoline 

Downstream Products

• 923036-30-0 N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-(7-p-toluenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1354621-59-2 C₁₄H₂₂N₂ 
• 1259404-17-5 tasocitinib 
• 384338-23-2 (1-benzyl-4-methyl-piperidin-3-yl)-methyl-amine 
• 374822-48-7 C₆H₁₃NO 

Relevant articles and documents

Short enantioselective total synthesis of (+)-tofacitinib

An enantioselective total synthesis of Tofacitinib (CP-690,550), a Janus tyrosine kinase (JAK3) specific inhibitor has been achieved from the readily available 4-piperidone. Proline catalysed hydroxylation is the key step for the synthesis of enantiopure 1-benzyl-4-methylpiperidin-3-ol.

η6-Arene CH?O Interaction Directed Dynamic Kinetic Resolution – Asymmetric Transfer Hydrogenation (DKR-ATH) of α-Keto/enol-Lactams

A dynamic kinetic resolution – asymmetric transfer hydrogenation (DKR-ATH) methodology of α-keto/enol-lactams was developed. We also propose a possible catalytic mechanism evolving a transition state stabilized by η6-arene CH?O interaction. The efficient approach can be applied to a wide range of substrates including non-aryl ones which would be difficult to prepare by other asymmetric reduction methods. (Figure presented.).

Method for preparing lactam compound

The invention relates to a preparation method of a lactam compound, and belongs to the field of medicinal chemistry. The preparation method comprises the following steps: carrying out an asymmetric hydrogenation reaction on raw materials under the action of a ruthenium catalyst and a hydrogen donor reagent, and carrying out a post treatment to obtain the target compound. The product obtained by the method is high in ee value, the method is simple and convenient, and the target compound can be easily, conveniently and efficiently obtained.

Asymmetric Synthesis of a Key Intermediate for Tofacitinib via a Dynamic Kinetic Resolution-Reductive Amination Protocol

We report the first example of a catalytic asymmetric reductive amination under dynamic kinetic resolution (DKR) conditions for the preparation of a chiral amine as a key intermediate toward Tofacitinib, an active pharmaceutical ingredient developed by Pfizer. Such a protocol allows the preferential formation of a single product out of four possible diastereomers of the chiral amine starting from the corresponding racemic ketone. The chiral iridium catalyst able to perform such a feast was discovered through a mix of high-throughput screening, racemization study, and reaction optimization.

Formal asymmetric synthesis of (+)-tofacitinib

Tofacitinib is an efficient and selective Janus kinase 3 (JAK3) inhibitor, and is used as an immunosuppressant drug for the treatment of rheumatoid arthritis and transplant patients. Herein we report a concise formal asymmetric synthesis of tofacitinib from homochiral 1,3-dioxolanone 10b, which was elaborated through a highly stereoselective Michael addition followed by solvent-free removal of the chiral auxiliary and ring cyclization to furnish chiral imide 8. The preparation of tofacitinib's precursor 16 could be obtained after reduction of 8 followed by sequential oxidation, reductive amination and SNAr reactions.

A supporting france for cloth as the starting material of the preparation method (by machine translation)

The invention discloses a method for supporting france for cloth starting material N - ((3 R, 4 R) - 4 - methyl - 1 - benzyl - 3 - piperidinyl) - N - methyl - 7 - paratoluene sulfonyl - 7 H - pyrrolo [2, 3 - D] pyrimidine - 4 - amine (I) synthetic method, specific steps are as follows: to 4 - methyl pyridine as the starting material, with the benzyl chloride undergo nucleophilic substitution by the 4 - methyl - 1 - phenylmethyl - pyridine hydrochloride, under the action of the sodium borohydride reduction reaction, borohydrite - oxidation reaction, hydroxy oxidation, the introduction of the reductive amination of the stereo selectivity of the two chiral center, through a readily available and inexpensive chiral acid (L - DTTA) splitting, to obtain optically pure intermediates (3 R, 4 R) - (1 - benzyl - 4 - methyl - piperidin - 3 - yl) - methylamine, and finally with the 4 - chloro pyrrolo pyrimidine condensation is obtained. The whole method raw materials are easy, simple operation, after treatment is easy, and the cost is low. (by machine translation)

Oxidation of carbon-boron bonds

The present invention relates to a scaleable process for the oxidation of carbon-boron bonds with Oxone.

Pyrrolo[2,3-d]pyrimidine compounds

A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.

Oxidation of carbon-boron bonds

The present invention relates to a scaleable process for the oxidation of carbon-boron bonds with Oxone?.

A safe, scaleable method for the oxidation of carbon-boron bonds with Oxone

A new procedure for the oxidation of carbon-boron bonds to the corresponding alcohol with Oxone is described. (C) 2000 Elsevier Science Ltd.